Agnieszka is a scientist with background in biomedical engineering and medical imaging. She used cutting edge biotech tools, including customized imaging robots, 3D modelling and VR, to innovate medical research all over the world, including forensic medicine in Switzerland, space medicine in Austria and translational science in Singapore. She is currently a PhD candidate at the Centre for Human Psychopharmacology at Swinburne University in Australia. Agnieszka is devoted to science outreach, extensively advocating for open-science communication, community led research and outcome transparency. For her outreach efforts, she won the best speaker award at 3D MED Australia and the MiLabs Image of the Year award, among others. Her work has been displayed worldwide, including Shanghai EXPO, Florence Biennale or Sounds of Space Exhibition in Austria. Agnieszka’s academic work was published in the Journal of Forensic Radiology and Imaging, and the Journal of Nuclear Medicine. As a freelance journalist, Agnieszka produced numerous articles on altered states of consciousness, including Transcendental Therapy: Mysticism, Psychedelics and Mental Health article for the prestigious Przekroj magazine.
Prash, a medical doctor and former Neuropsychiatry Fellow at The Alfred Hospital in Melbourne, is one of Australia’s leading advocates for accessible psychedelic-assisted psychotherapy. In this capacity, Prash is a clinical adviser to the Australian Psychedelic Society and is frequently sought for his thought leadership on the subject of the therapeutic uses of psychedelic substances. Prash is also the founder of pioneering digital currency brokerage Caleb & Brown, named “Fintech Startup of the Year” in 2018 by the Australian Stockbrokers & Financial Advisors Association. Caleb & Brown, Australia’s largest personalised cryptocurrency brokerage firm, widens the suite of traditional wealth management services through the provision of bespoke digital currency solutions. Prash has a Bachelor of Medicine and Bachelor of Surgery (Honours) from Monash University in Melbourne, a Masters in Psychological Medicine from the University of Melbourne, and has written for a number of publications including The Lancet and the Australian & New Zealand Journal of Psychiatry. In 2018, Prash was awarded Young Executive of the Year by the Australia-wide Indian Executive Council.
A graduate of the Faculty of Multimedia Communication at the Academy of Fine Arts in Poznań (currently the University of Arts in Poznań). He graduated in 2010, making a film in the animation studio of prof. Jacek Adamczak. From 2010, assistant in the 3rd Animation Studio. From 2014, head of the Department of Animation at the Faculty of Animation of the University of Arts in Poznań. He deals with interactive film, computer games, VR, and modern technologies Filmography: 3 is a magic number, City Rhythms, Monday… (2007), Institution, City (2008), Vip (2009), Virtual? Reality (2009), Babel (2010), Ars moriendi (2014).
Renee is a Clinical Psychologist who has recently relocated to Australia after a long career in the UK as a Consultant in the NHS and more recently as an Honorary Research Fellow at imperial College London in the study of psilocybin for treatment-resistant depression. She was responsible for leading in service development for people with complex emotional needs in the UK and specialised in training clinicians for this work. Renee was a key member of developing psychedelic interest groups and in establishing and running a psychedelic Integration Circle in Brighton prior to leaving the UK. She is currently based in Melbourne, working in private practice and part of the developing Australian community in psychedelic-assisted psychotherapy research and clinical service.
Tristan is an entrepreneur, software developer and product manager, who’s passionate about satoshi’s and psychedelics. In 2017, Tristan founded Sempo, an open-source payments company that processes over one million payments per year for non-profits such as Oxfam and Red Cross. For his work at Sempo, he’s been recognized as a Forbes 30 Under 30 Fintech Entrepreneur, 7News Young Achiever Award and Commonwealth Bank Blockchain Award.
Brock is a former AFL player whose career spanned 11 years whilst playing for 2 clubs, Carlton and Melbourne. During this time, Brock developed a passion for equity capital markets and studied successfully for his RG146 in managed investments, securities and derivatives. Post career, Brock began studying a bachelor of finance at Latrobe University, before transferring to Melbourne University to study commerce, where he eventually deferred to focus on vocation and business opportunities. He has worked as an equities analyst, corporate advisor and partnerships manager, getting a breadth of experience across the investment vertical. More recently, Brock has become quite a vocal proponent and ambassador in the mental health space, given his extensive lived experience with a number of underlying psychiatric conditions for 10+ years. He started reading about the therapeutic potential of psychedelics 3 years ago and has now found his new passion project and is inspired to be a part of the paradigm shift in how society and medicine treat the mentally vulnerable.
As Clinical Lead of the Psilocybin for Depression Study at Imperial College London, Dr Rosalind Watts focused on how psychedelics can increase ‘Connectedness to self, others and the world’. Her qualitative research led her to develop a psychedelic therapy model, ‘Accept, Connect, Embody (ACE)’, a framework for group-based integration of psychedelic experiences ‘Accept, Connect, Embody, Restore (ACER)’, and a psychometric tool for measuring connectedness, the Watts Connectedness Scale (WCS). Having piloted her group integration program at Synthesis Institute, Dr Watts has now founded the ACER community online, where people all over the world can follow a year-long integration process together. The ‘Twelve Trees’ process aims to help people maintain connectedness to self, others and the natural world in the months and years after psychedelic experiences. Dr Watts co-founded the UK's first psychedelic integration group, sits on Advisory Boards for The USONA Institute, The Synthesis Institute and Enosis Therapeutics, and is a consultant psychologist for Small Pharma who are investigating DMT as a treatment for depression.
Murat is a Clinical Neuropsychologist and NHMRC Principal Research Fellow. As well as being BrainPark's Founding Director, Murat is Leader of the Addiction and Mental Health Program within the Turner Institute for Brain and Mental Health is a Principal Investigator on MDMA and psilocybin clinical trials. His work combine's neuroscience with lifestyle and technology-based immersive interventions (such as physical exercise, mindfulness mediation, yoga, virtual reality, and cognitive training) to drive the creation of a new generation of lifestyle and technology-based tools and strategies that enable engaging and effective monitoring and enhancement of mental wellbeing, particularly for people with compulsive behaviours; from unhealthy habits through to addictions and obsessive compulsive disorder. Murat has been named in the 0.1% of the most Highly Cited (HiCi) researchers in the world on five occasions (2015, 17-20). Murat is an advisor to Enosis, and does not hold equity in the company or receive remuneration for this role.
Dr Margaret Ross (PsyD) is the Chief Principal Investigator and clinical lead for Australia’s first psilocybin-assisted psychotherapy study treating depression and anxiety in the terminally ill. Her study is a world first investigating psilocybin assisted therapy for all palliative conditions, and sees Dr Ross pioneering a new frontier in psychedelic medicine. Dr Ross combines oversight of this ground-breaking trial with palliative medicine clinical work in her role as Senior Clinical Psychologist and Researcher at St Vincent’s Hospital in Melbourne and also trains clinicians in emerging psychedelic assisted therapy drug trials. She regularly lectures medical students and specialist clinicians in psychosocial aspects of palliative medicine and cancer care. Margaret is an advisor to Enosis, and does not hold equity in the company or receive remuneration for this role.
Dr Nigel Strauss, a psychiatrist with 40 years of clinical experience, is an Honorary Consultant at St Vincent's Hospital Melbourne, an Honorary Research fellow within Psychiatry at the University of Melbourne, and a Clinical Associate within the Centre of Mental health, Swinburne University. He has a particular interest in Psychedelic Assisted Psychotherapy and is a trained psychotherapist with the Multidisciplinary Association of Psychedelic Science (MAPS). He is also a Member of the Scientific Advisory Board, European Foundation for Psychedelic Science (MIND). Dr Strauss is currently an Investigator and therapist in several trials in Australia using Psychedelic medicines. He is a Principal Investigator and therapist in the first Australian trial using psilocybin-assisted psychotherapy for treatment-resistant depression at Swinburne University and an Investigator and therapist in the very first Australian trial using psilocybin-assisted psychotherapy for end of life anxiety and depression at St Vincents Hospital Melbourne. He is an Investigator and Sponsor of a trial at Monash University using MDMA-assited psychotherapy for treatment resistant PTSD. Dr Strauss is also the Medical Director of the Millswyn Clinic in South Yarra Melbourne, established by him in 1983 which is a private outpatient psychiatric facility providing a range of Psychiatric and Psychological services to the public.
Martin Williams is a research fellow at the Turner Institute for Brain and Mental Health at Monash University. His interests in psychology and pharmacology have led him towards the multidisciplinary study of psychoactive compounds and their roles in contemporary society. Martin is a founding member of Entheogenesis Australis (EGA, www.entheogenesis.org), an educational charity focused on the historical use and societal impacts of medicinal plants and chemicals, and founding President of Psychedelic Research in Science & Medicine (PRISM, www.prism.org.au), a health-promotion charity established to support and coordinate Australian contributions to global academic research into the medical and psycho-social applications of psychoactive drugs. Martin is co-lead on the St Vincent’s Hospital Melbourne Phase 2 trial of psilocybin-assisted therapy for depression and anxiety associated with terminal illness, and co-investigator on the upcoming clinical trials of psilocybin-assisted therapy for treatment-resistant depression at Swinburne University in Melbourne, and MDMA-assisted therapy for PTSD at Edith Cowan University in Perth. Martin is a regular speaker and commentator on psychedelic science in Australia, and reviewer of psychedelic science submissions for several international journals.
Paul is Head of Clinical Psychedelic Research at Monash University, and Chief Principal Investigator on a program of psychedelic trials at Monash University. He has an Honours in Neuroscience and a PhD in Psychology from the University of Melbourne, and has Adjunct or Honorary appointments at St Vincent’s Hospital, Macquarie University, Deakin University, and the University of Melbourne. He is an Investigator on a number of Australia’s first few ethically-approved psychedelic trials, coordinates Australia’s first applied psychedelic therapist training programs, has obtained the first industry funding and partnership for psychedelics in Australia, is establishing Australia’s largest psychedelic trial, and leads Australia’s first clinical psychedelic lab. His work is focused on developing a rigorous program of research in psychedelic medicine that seeks to evaluate therapeutic effects, innovate on treatment design, mitigate known risks, explore potential drawbacks, and understand therapeutic mechanisms. Paul is an advisor to Enosis, and does not hold equity in the company or receive remuneration for this role.